T1	Fact 65 242	There are a number of challenges facing cell therapies; from the first step of isolating cells to their eventual stable and successful long-term integration into the myocardium.
A1	Source T1 Averred
T2	KT_cue 65 74	There are
R1	Cue Arg1:T2 Arg2:T1	
T3	Fact 243 343	Heart attacks and subsequent myocardial infarction result in the loss of millions of cardiomyocytes.
A2	Source T3 Averred
T4	KT_cue 243 303	Heart attacks and subsequent myocardial infarction result in
R2	Cue Arg1:T4 Arg2:T3	
T5	Fact 344 481	For cell therapies to be successful, generating sufficient amounts of cardiomyocytes to adequately replace these lost cells is paramount.
T6	KT_cue 381 470	generating sufficient amounts of cardiomyocytes to adequately replace these lost cells is
R3	Cue Arg1:T6 Arg2:T5	
T7	Fact 482 681	Targeting proliferation pathways, such as the Hippo signalling pathway, to enhance the generation of iPS cells and subsequent iPS- derived cardiomyocytes for cell therapies has therapeutic potential.
A3	Source T7 Averred
T8	KT_cue 482 515;554 658	Targeting proliferation pathways, to enhance the generation of iPS cells and subsequent iPS- derived cardiomyocytes for cell therapies has
R4	Cue Arg1:T8 Arg2:T7	
T9	Fact 683 791	The first stage of induced pluripotent stem cell production, reprogramming, is currently not very efficient.
A4	Source T9 Averred
T10	KT_cue 683 743;759 761	The first stage of induced pluripotent stem cell production, is
R5	Cue Arg1:T10 Arg2:T9	
T11	Observation 792 920	YAP activity has been observed to enhance the reprogramming of fibroblasts to induced pluripotent stem cells (Lian et al. 2010).
A5	Source T11 Non-integral_information_led_citation
T12	KT_cue 792 825	YAP activity has been observed to
R6	Cue Arg1:T12 Arg2:T11	
T13	Source_cue 901 920	(Lian et al. 2010).
R7	Cue Arg1:T13 Arg2:T11	
T14	Fact 921 1050	Fibroblasts express significantly lower levels of YAP than iPS cells, that have been reprogrammed from the fibroblast population,
A6	Source T14 Non-integral_information_led_citation
T15	KT_cue 921 940	Fibroblasts express
R8	Cue Arg1:T15 Arg2:T14	
T21	Observation 1115 1147	Further investigation found that
A10	Source T21 General_reference
A11	Verb_noun T21 Certainty
T22	Source_cue 1115 1136	Further investigation
R13	Cue Arg1:T22 Arg2:T21	
T23	KT_cue 1115 1142	Further investigation found
R14	Cue Arg1:T23 Arg2:T21	
T24	Verb_cue 1115 1147	Further investigation found that
R15	Cue Arg1:T24 Arg2:T21	
T25	Analysis 1148 1302	potential YAP binding targets include genes which are also targeted by factors, such as Nanog and Oct4, which are essential for ES and iPS cell phenotype.
A12	Source T25 General_reference
A13	Certainty_Level T25 L1
T26	KT_cue 1148 1157	potential
R16	Cue Arg1:T26 Arg2:T25	
T27	CL_cue 1148 1157	potential
R17	Cue Arg1:T27 Arg2:T25	
T28	Fact 1303 1435	As previously mentioned, knockdown of LATS2 also leads to increased iPS colony formation following reprogramming (Qin et al., 2012).
A14	Source T28 Non-integral_information_led_citation
T29	Source_cue 1303 1327;1416 1435	As previously mentioned, (Qin et al., 2012).
R18	Cue Arg1:T29 Arg2:T28	
T30	KT_cue 1328 1360	knockdown of LATS2 also leads to
R19	Cue Arg1:T30 Arg2:T28	
T31	Fact 1437 1508	Animals such as newts and zebra fish are capable of heart regeneration.
A15	Source T31 Averred
T32	KT_cue 1437 1477	Animals such as newts and zebra fish are
R20	Cue Arg1:T32 Arg2:T31	
T34	Observation 1509 1646	Recently, the Hippo pathway has been observed to be involved in cardiomyocyte proliferation during newt heart regeneration (Singh, 2013).
A17	Source T34 Non-integral_information_led_citation
T35	KT_cue 1519 1560	the Hippo pathway has been observed to be
R21	Cue Arg1:T35 Arg2:T34	
T36	Source_cue 1632 1646	(Singh, 2013).
R22	Cue Arg1:T36 Arg2:T34	
T37	Fact 1647 1669	It is not yet known if
A18	Source T37 Averred
A19	Neg_CL T37
T38	KT_cue 1647 1666	It is not yet known
R23	Cue Arg1:T38 Arg2:T37	
T39	Analysis 1667 1808	if modification of the Hippo pathway in stem-cell derived cardiomyocytes will enhance the proliferative capacity and survival of these cells.
A20	Source T39 Averred
A21	Certainty_Level T39 L2
A22	Modality T39
T40	KT_cue 1670 1752	modification of the Hippo pathway in stem-cell derived cardiomyocytes will enhance
R24	Cue Arg1:T40 Arg2:T39	
T41	Modality_cue 1670 1752	modification of the Hippo pathway in stem-cell derived cardiomyocytes will enhance
R25	Cue Arg1:T41 Arg2:T39	
T42	Fact 1809 1987	Cardiac specific knock outs of components of the Hippo pathway result in increased cardiomyocyte proliferation and survival, in new-born mice and adult mouse hearts respectively.
A23	Source T42 Averred
T43	KT_cue 1809 1881	Cardiac specific knock outs of components of the Hippo pathway result in
R26	Cue Arg1:T43 Arg2:T42	
T44	Analysis 1988 2120	Based on this, genetic ablation of components of  the Hippo pathway could enhance the survival and proliferative capacity of iPS- CM
A24	Source T44 Averred
A25	Certainty_Level T44 L1
A26	Modality T44
T45	KT_cue 2003 2069	genetic ablation of components of  the Hippo pathway could enhance
R27	Cue Arg1:T45 Arg2:T44	
T46	CL_cue 2003 2069	genetic ablation of components of  the Hippo pathway could enhance
R28	Cue Arg1:T46 Arg2:T44	
T47	Modality_cue 2003 2069	genetic ablation of components of  the Hippo pathway could enhance
R29	Cue Arg1:T47 Arg2:T44	
T48	Analysis 2121 2190	and therefore increase the potential of cardiac regenerative therapy.
A27	Source T48 Averred
A28	Certainty_Level T48 L4
T49	KT_cue 2125 2134	therefore
R30	Cue Arg1:T49 Arg2:T48	
T50	CL_cue 2135 2143	increase
R31	Cue Arg1:T50 Arg2:T48	
T51	Analysis 2192 2273	Dysregulation of the Hippo pathway can result in uncontrolled cell proliferation.
A29	Source T51 Averred
A30	Certainty_Level T51 L1
A31	Modality T51
T52	KT_cue 2192 2240	Dysregulation of the Hippo pathway can result in
R32	Cue Arg1:T52 Arg2:T51	
T53	CL_cue 2192 2240	Dysregulation of the Hippo pathway can result in
R33	Cue Arg1:T53 Arg2:T51	
T54	Modality_cue 2192 2237	Dysregulation of the Hippo pathway can result
R34	Cue Arg1:T54 Arg2:T51	
T55	Fact 2274 2402	As a result, the Hippo pathway is becoming a prominent research subject in the field of cancer biology and potential treatments.
A32	Source T55 Averred
T56	KT_cue 2287 2316	the Hippo pathway is becoming
R35	Cue Arg1:T56 Arg2:T55	
T57	Fact 2403 2467	Manipulation of the pathway is also of interest in heart disease
A33	Source T57 Averred
T58	KT_cue 2410 2433	ation of the pathway is
R36	Cue Arg1:T58 Arg2:T57	
T59	Analysis 2468 2518	due to the low regenerative capacity of the heart.
A34	Source T59 Averred
A35	Certainty_Level T59 L4
T60	Source_cue 2468 2474	due to
R37	Cue Arg1:T60 Arg2:T59	
T61	Fact 2519 2614	Attenuation of the pathway during development results in increased cardiomyocyte proliferation.
A36	Source T61 Averred
T62	KT_cue 2519 2575	Attenuation of the pathway during development results in
R38	Cue Arg1:T62 Arg2:T61	
T63	Analysis 2615 2749	Increasing the proliferation of cardiomyocytes will advance cell therapy efforts as a potential treatment after myocardial infarction.
A37	Source T63 Averred
A38	Certainty_Level T63 L2
A39	Modality T63
T64	KT_cue 2626 2674	the proliferation of cardiomyocytes will advance
R39	Cue Arg1:T64 Arg2:T63	
T65	CL_cue 2626 2674	the proliferation of cardiomyocytes will advance
R40	Cue Arg1:T65 Arg2:T63	
T66	Modality_cue 2626 2674	the proliferation of cardiomyocytes will advance
R41	Cue Arg1:T66 Arg2:T63	
T67	Fact 2750 2898	Currently, a large number of cardiomyocytes which can survive in adverse conditions are needed for cell based therapies to be clinically successful.
A40	Source T67 Averred
A41	Modality T67
T68	KT_cue 2761 2844	a large number of cardiomyocytes which can survive in adverse conditions are needed
R42	Cue Arg1:T68 Arg2:T67	
T69	Modality_cue 2761 2811	a large number of cardiomyocytes which can survive
R43	Cue Arg1:T69 Arg2:T67	
T70	Fact 2899 3039	The phenotype of iPS-CMs are more similar to neonatal cardiomyocytes than adult cardiomyocytes, especially in relation to electrophysiology.
A42	Source T70 Averred
T71	KT_cue 2899 2927	The phenotype of iPS-CMs are
R44	Cue Arg1:T71 Arg2:T70	
T72	Analysis 3040 3074	As suggested by Chan et al (2014),
A43	Source T72 Integral_citation
A44	Certainty_Level T72 L1
T73	KT_cue 3043 3052	suggested
R45	Cue Arg1:T73 Arg2:T72	
T74	CL_cue 3043 3052	suggested
R46	Cue Arg1:T74 Arg2:T72	
T75	Source_cue 3053 3074	by Chan et al (2014),
R47	Cue Arg1:T75 Arg2:T72	
T76	Analysis 3075 3183	iPS-CMs will need to have a more mature phenotype to successfully integrate without causing any arrhythmias.
A45	Source T76 Averred
A46	Modality T76
T77	KT_cue 3075 3100	iPS-CMs will need to have
R48	Cue Arg1:T77 Arg2:T76	
T78	Modality_cue 3075 3100	iPS-CMs will need to have
A47	Modality T78
R49	Cue Arg1:T78 Arg2:T76	
T79	Analysis 3184 3400	Further investigation into enhancing the efficiency of the differentiation and the survival of the generated iPS-CM by targeting the Hippo pathway will increase the therapeutic potential of this form of cell therapy.
A48	Source T79 Averred
A49	Certainty_Level T79 L2
A50	Modality T79
T80	KT_cue 3184 3344	Further investigation into enhancing the efficiency of the differentiation and the survival of the generated iPS-CM by targeting the Hippo pathway will increase
R50	Cue Arg1:T80 Arg2:T79	
T81	CL_cue 3184 3344	Further investigation into enhancing the efficiency of the differentiation and the survival of the generated iPS-CM by targeting the Hippo pathway will increase
R51	Cue Arg1:T81 Arg2:T79	
T82	Modality_cue 3184 3344	Further investigation into enhancing the efficiency of the differentiation and the survival of the generated iPS-CM by targeting the Hippo pathway will increase
R52	Cue Arg1:T82 Arg2:T79	
T83	Investigation 3402 3581	This study will consider the role of the Hippo pathway in enhancing the potential of induced pluripotent stem cell derived cardiomyocytes (iPS-CM) for use in cardiac regeneration.
A51	Source T83 Self_other
T84	KT_cue 3402 3426	This study will consider
R53	Cue Arg1:T84 Arg2:T83	
T85	Source_cue 3402 3426	This study will consider
R54	Cue Arg1:T85 Arg2:T83	
T86	Analysis 3582 3643	iPS-CM are regarded as a promising cell type for cell therapy
A52	Source T86 Averred
T87	KT_cue 3582 3604	iPS-CM are regarded as
R55	Cue Arg1:T87 Arg2:T86	
T88	Analysis 3644 3690	due to their autologous and cardiac phenotype.
A53	Source T88 Averred
A54	Certainty_Level T88 L4
T89	KT_cue 3644 3650	due to
R56	Cue Arg1:T89 Arg2:T88	
T90	Investigation 3691 3902	We targeted this pathway by: 1) Ablating Mst1, the major upstream regulator of Hippo pathway, in skin fibroblasts prior to reprogramming; 2) Overexpressing YAP, the major downstream effector of Hippo, in iPS-CM.
A55	Source T90 Emphasised
T91	KT_cue 3691 3702	We targeted
R57	Cue Arg1:T91 Arg2:T90	
T92	Source_cue 3691 3702	We targeted
R58	Cue Arg1:T92 Arg2:T90	
A56	Certainty_Level T86 L2
T93	CL_cue 3582 3604	iPS-CM are regarded as
R59	Cue Arg1:T93 Arg2:T86	
T16	Analysis 1051 1061	suggesting
A7	Verb_noun T16 Speech_act_communication
A8	Source T16 Non-integral_information_led_citation
A9	Certainty_Level T16 L1
T17	KT_cue 1051 1061	suggesting
R9	Cue Arg1:T17 Arg2:T16	
T18	CL_cue 1051 1061	suggesting
R10	Cue Arg1:T18 Arg2:T17	
T19	Verb_cue 1051 1061	suggesting
R11	Cue Arg1:T19 Arg2:T18	
T20	Fact 1062 1114	YAP contributes to pluripotency (Lian et al., 2010).
A16	Source T20 Non-integral_information_led_citation
T33	KT_cue 1062 1080	YAP contributes to
R12	Cue Arg1:T33 Arg2:T20	
T94	Source_cue 1094 1114	(Lian et al., 2010).
R60	Cue Arg1:T94 Arg2:T20	
A57	Certainty_Level T76 L2
T95	CL_cue 3075 3100	iPS-CMs will need to have
R61	Cue Arg1:T95 Arg2:T76	
A58	Source T5 Averred
